Prolonged half-life and preserved enzymatic properties of factor IX selectively PEGylated on native N-glycans in the activation peptide
- 25 August 2011
- journal article
- Published by American Society of Hematology in Blood
- Vol. 118 (8), 2333-2341
- https://doi.org/10.1182/blood-2011-02-336172
Abstract
Current management of hemophilia B entails multiple weekly infusions of factor IX (FIX) to prevent bleeding episodes. In an attempt to make a longer acting recombinant FIX (rFIX), we have explored a new releasable protraction concept using the native N-glycans in the activation peptide as sites for attachment of polyethylene glycol (PEG). Release of the activation peptide by physiologic activators converted glycoPEGylated rFIX (N9-GP) to native rFIXa and proceeded with normal kinetics for FXIa, while the Km for activation by FVIIa–tissue factor (TF) was increased by 2-fold. Consistent with minimal perturbation of rFIX by the attached PEG, N9-GP retained 73%-100% specific activity in plasma and whole-blood–based assays and showed efficacy comparable with rFIX in stopping acute bleeds in hemophilia B mice. In animal models N9-GP exhibited up to 2-fold increased in vivo recovery and a markedly prolonged half-life in mini-pig (76 hours) and hemophilia B dog (113 hours) compared with rFIX (16 hours). The extended circulation time of N9-GP was reflected in prolonged correction of coagulation parameters in hemophilia B dog and duration of effect in hemophilia B mice. Collectively, these results suggest that N9-GP has the potential to offer efficacious prophylactic and acute treatment of hemophilia B patients at a reduced dosing frequency.Keywords
This publication has 51 references indexed in Scilit:
- Functional characteristics of N8, a new recombinant FVIIIHaemophilia, 2010
- Optimizing thrombelastography (TEG) assay conditions to monitor rFVIIa (NovoSeven®) therapy in haemophilia a patientsThrombosis Research, 2010
- Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trialAnnals Of The Rheumatic Diseases, 2008
- Immune response after neonatal transfer of a human factor IX-expressing retroviral vector in dogs, cats, and miceThrombosis Research, 2007
- Pharmacokinetic Consequences of PegylationDrug Delivery, 2006
- World Federation of Haemophilia Programs in Developing CountriesSeminars in Thrombosis and Hemostasis, 2005
- An important role for the activation peptide domain in controlling factor IX levels in the blood of haemophilia B miceThrombosis and Haemostasis, 2005
- Optimizing factor prophylaxis for the haemophilia population: where do we stand?Haemophilia, 2004
- Activation Peptide of Human Factor IX Has Oligosaccharides O-Glycosidically Linked to Threonine Residues at 159 and 169Biochemistry, 1994
- The molecular basis of blood coagulationCell, 1988